Moore Malcolm J
Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6. doi: 10.1053/j.seminoncol.2005.07.017.
Single-agent gemcitabine is currently the standard treatment for advanced pancreatic cancer. A majority of recent phase III trials have shown either marginal or no improvement in survival using gemcitabine in combination with other chemotherapeutic and novel agents. Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer.
单药吉西他滨目前是晚期胰腺癌的标准治疗方法。最近的大多数III期试验表明，吉西他滨与其他化疗药物及新型药物联合使用，在生存期方面要么仅有微小改善，要么没有改善。我们小组最近报告称，吉西他滨与厄洛替尼联合使用可显著延长晚期胰腺癌患者的生存期，并改善无进展生存期。
